anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dental caries is a dynamic and multifactorial process. Occurrence of dental caries is affected by several factors including quantity and composition of saliva, oral microflora and patient-related parameters including general health and lifestyle, such as the use of fluoride-containing toothpastes and diet.

Caries risk is defined as the probability of developing caries in the future. The incidence of the disease can be either primary (New caries lesions) or secondary (Progression of lesion or reactivation of caries lesions). Caries risk assessment (CRA) is important for the successful application of a minimum intervention dentistry philosophy in the management of dental caries. Patients, with active caries at the time of visit, need the CRA to identify the factors that are most likely to progress in the disease process. The CRA is one of the methods for managing the caries of patients.

Riley et al. showed that the anti-caries agents were widely used in dental clinics, while the CRA was performed by a few dental clinics. In a study of Gaskin et al., 63.5% of subjects agreed with the use of minimal intervention dentistry. In a study of Shah et al., 36% of dentists accepted the use of restorative materials and CRA-based methods, and 15.5% also strongly agreed with CRA for all patients. In a study by Rayapudi and Usha, 81% of participants agreed with CRA in patients. In a study by Riley et al. about the use of CRA by dentists in children, 73% of dentists reported having CRAs for people aged 6 to 18 years. In another study by Riley et al., 69% of dentists performed CRA for patients, and 57% of dentists who performed CRA had considered an individualized caries prevention programs for their patients. Hurlbutt et al. showed that caries management by the CRA is an example of patient care that has the best practice rather than traditional therapies.

Afshar et al. claimed that the CRA is a conservative approach that can prevent waste of time, energy and finances. Evaluating the management of the results of illness in certain periods of time leads to less dental tissues wasting. People's knowledge of CRA in patients leads to more conservative treatment. Due to limited studies in this field and the absence of data about using CRA in Egypt, Especially on dental residents, this study was conducted to evaluate the knowledge, attitude and practice regarding Caries Risk Assessment among pediatric and Conservative Dental Residents in Faculty of Oral and Dental Medicine, Cairo University.
In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
Participants randomized to the waitlist control arm will be offered what is considered "usual care" at the ACS: the provision of the ACS Telephone Hotline number (1-800- 227-2345) and direction to the ACS website (www.cancer.org) where participants can find many resources for caregivers, including links to the ACS Caregiver ToolKit. They will complete assessments at time points that correspond with the completion of assessments in the CCC Workshop arm: after consent as soon as they are able (T1), about 2 months (± 4 weeks) after T1 (T2), and about 2-3 months after T2 (T3). Upon completion of all study assessments the waitlist control arm participants will be offered the opportunity to complete the CCC Workshop.
Ventilator-associated pneumonia (VAP) is one of the major causes of morbidity and mortality in the ICU, accounting for 25% of the total infections occurring in this setting and 50% of all antibiotic prescriptions in patients who are mechanically ventilated.1,2 The incidence of VAP depends not only on the type of the institution, the preventive measures and therapeutic approaches that are used, but also on the type of surveillance systems by which incidence is estimated. There are reports of incidence across different settings varying from 1.4 up to 42.8 episodes of VAP/1,000 ventilation-days.2 Patients with VAP have significantly longer ICU and hospital lengths of stay compared with similar patients without VAP.3,4 Consequently, the economic burden of VAP is considerable, leading to significant draining of resources. Even after adjusting for underlying severity of illness, the attributable cost of VAP amounts to several thousands of US dollars per patient.5 There is evidence that using shorter antibiotic regimens may help in decreasing antimicrobial resistance and reducing drug-related adverse events.6 Moreover, short-course treatments were found to be as effective as longer-course antibiotic treatment.7,8 In a pooled analysis of four randomized trials in VAP comparing shorter versus long duration of antibiotics in the management of VAP, no difference in the mortality was found.9 There was an increase in the antibiotic free days in the short course antibiotic arm. There was no difference in the number of relapses of VAP with either modality of treatment.9 In another analysis of six studies with 1088 subjects, there was a higher occurrence of relapses of VAP due to non-lactose fermenting gram negative organism.10 However, there was no difference in the mortality rates.10 The problem with both these meta-analyses was that they did not provide information regarding the outcomes of VAP due to Acinetobacter baumanii.9,10 Also, the short duration strategy included studies that randomized patients to seven to eight days and ten-to fifteen days in the long duration strategy. None of the previous studies has provided information about outcomes of VAP due to Acinetobacter baumanii. In our observation, most of the episodes of VAP in our ICU are due to drug resistant Acinetobacter baumanii. We hypothesize that the use of short course of antibiotics in the treatment of VAP due to drug resistant Acinetobacter baumanii (sensitive to carbapenems and/or colistin only) may result in a higher antibiotic-free days and drug related adverse events, in comparison to a longer duration of antibiotics. In this study, we propose to study a 7-day versus 14-day course of antibiotics in patients with drug-resistant Acinetobacter baumanii.
PURPOSE:To collect a low-boiling essence component volatile in extraction process by a sure and simple means, to reduce operation man-hour, to eliminate drawback of liquid essence separation during preservation and to obtain the titled essence, by treating a Chinese herbal remedy by a specific plant method. CONSTITUTION:A crude drug or a Chinese herbal remedy, prescribed crude drug (e.g. powdered Cinnamon bark, Zingiberis rhizoma, Japanese angelica root, Cnidium, etc.) is extracted with a solvent for a given temperature (30-100 deg.C and 80-100 deg.C for 30-120min in the case of using water as a solvent) for a given period (3-150hr, preferably 3-48hr) under heating. In the heating extraction process, only initial distillate at least from a reaching period of a given temperature to a period after 1/10-1/3 the whole extraction hours elased is condensed. The extracted solution is concentrated to give soft essence of Chinese herbal remedy. The condensed solution of the initial distillate is collected in liquid cyclodextrin and the solution is blended with the soft essence to give soft essence of Chinese herbal remedy of long-period stabilization type.
The process, for making a resin for human use in treatment for reduction of cholesterol and providing a system for fixing bile salts and interrupting entero-hepatic re-circulation, consists of (a) reacting a mixt. of vinylamine monomer with benzoyl peroxide in toluene soln.; (b) filtering and washing with toluene the insoluble polymer formed; (c) dissolving in DMF and treating with epichlorhydrin; (d) immersing the soln. in a propanol-water mixt. and treating with glycidyl ammonium chloride; and (e) filtering and washing the prod. with methanol.
This study will be enhancing current patient navigation at the participating 5 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
The active treatment arm consists of text messages with information, motivation, and behavioral skill based text messages aimed at increasing HIV testing, our primary outcome. Secondary outcomes include STI testing, PrEP uptake, condomless sex, and discussions with providers about PrEP/HIV care. Hypothesized mediators of HIV testing include testing/prevention information, motivation, and behavioral skills. All participants will receive 8-10 messages/day for 6 weeks, with a 1 week booster session following the intervention. In the active treatment arm, participants will have full access to interactive features such as quizzes, badges, an external chatbot feature, a website with sexual health resources, and a group chat feature (a group of 3-5 total participants with whom participants can discuss program content) to promote engagement and enhance learning and skills acquisition.
Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
Anti-inflammatory Diet: This arm will focus on adjusting dietary practices to eat foods that have lower amounts of inflammatory foods that might help reduce overall inflammation in the brain and body. This arm will introduce patients to an integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
Irinotecan serves as a water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold; however, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan [see Clinical Pharmacology (12.3) ].The precise contribution of SN-38 to the activity of irinotecan hydrochloride injection is thus unknown. Both irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. A pH-dependent equilibrium exists between the two forms such that an acid pH promotes the formation of the lactone, while a more basic pH favors the hydroxy acid anion form.

Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types.
FIELD: biotechnology.SUBSTANCE: invention refers to biotechnology and veterinary medicine. Method for preparing the preparation for increasing non-specific body resistance, preventing and treating diseases of young farm animals involves mixing 90 pts. wt. 0.2-0.3% agar suspension and 2.5 pts. wt. Concentrate of purified polysaccharide complex of yeast cells. Then, while continuously stirring, the obtained mixture is added with 3.5 pts. wt. (-)2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]-thiazole hydrochloride, 5000000 ME of procaine-benzylpenicillin, 5000 mg of dihydrostreptomycin sulphate and 0.2 pts. wt. of formalin. Volume is adjusted with distilled water to 100 pts. wt. Prepared preparation is bottled in 50-100 ml bottles and sterilized.EFFECT: proposed preparation provides stimulating non-specific body resistance, preventing and treating respiratory, gastrointestinal and urogenital diseases of young farm animals, as well as expands range of agents for increasing activity of cell and humoral factors of nonspecific resistance and specific body immunogenesis.1 cl, 3 tbl, 4 ex
The present invention is directed to attenuated strains of enteroinvasive bacteria that express a peptide or protein related to an epitope of the malaria parasites of the genus Plasmodium. The bacterial strains of the invention which can multiply in a host without causing significant disease or disorder, and which express a Plasmodium-related peptide that induces a protective immune response against malaria, can be used in live vaccine formulations for malaria. In specific embodiments, a Plasmodium-related peptide can be expressed as a fusion protein, for example, with a bacterial enterotoxin. The invention also relates to methods for expression of malaria antigens or fragments thereof within attenuated enteroinvasive bacteria. In particular embodiments, the invention is directed to the expression by attenuated Salmonella spp. of epitopes of Plasmodium circumsporozoite proteins.
Functional electrical stimulation (FES) is a common and effective therapeutic approach for clinical treatments of shoulder subluxation. By applying low-frequency electrical stimulation to the target muscle groups, improvements may be observed in terms of muscle strength, subluxation, and passive humeral lateral rotation of the shoulder joint. In order to overcome issues regarding the integration of an FES and a rehabilitation robot, group members have designed a customized FES system approved by medical safety regulations. Despite sharing identical specifications with commercial models, the approved 2-channel FES system provides better integrity and control when working with the upper extremity rehabilitation robot. In this study, three patients with unilateral shoulder subluxation will be recruited. Limited shoulder x-ray photos shall be taken before, during, and after the FES shoulder subluxation treatment for studying the effects.
Stroke is a leading cause of impairment, with 20% of survivors requiring institutional care for 3 months afterward, and 15% to 30% being disabled permanently. A review in 2016 has shown that over the past four decades, a statistically significant trend in stroke incidence rate declined in high-income countries (42%) but in low- to middle-income countries, it was increasing to a greater than 100% trend over time. Functional recovery after a stroke is a complex and multifactorial process influenced by a combination of biopsychosocial and motor factors. Biopsychosocial factors encompass the interplay between biological, psychological, and social aspects of an individual's life that can influence their recovery trajectory. Motor factors, on the other hand, specifically focus on impairments and functional limitations related to movement and mobility. Only a few studies have explored the role of various biopsychosocial and motor factors in predicting functional recovery in stroke survivors and these studies have focused on the factors individually. Biologically, factors such as lesion location, stroke severity, age, and comorbidities have been shown to influence recovery outcomes. Psychologically, factors like motivation, self-efficacy, depression, and cognitive function can significantly impact a person's ability to engage in rehabilitation and regain functional abilities. Social factors, including social support, access to rehabilitation services, and socioeconomic status also play a critical role in facilitating or hindering recovery.

Likewise, motor factors, such as motor impairment, balance, gait, speed, and functional mobility are strong predictors of functional recovery. Motor recovery is closely associated with the reorganization of neural pathways and the restoration of motor function. Up to the researcher knowledge, there is currently limited literature available that thoroughly investigates the biopsychosocial and motor predictors of functional recovery in stroke survivors. Previous studies have only focused on examining these factors individually, without considering their collective impact on functional outcomes. As a result, there is a significant research gap in understanding how these factors interact and influence the recovery process.
Piglet birth weight is associated with preweaning survival, and its related traits have been included in the breeding program. Thus, understanding its genetic basis is essential. This study identified four birth weight-associated genomic regions on chromosomes 2, 4, 5, and 7 through genome-wide association study analysis in 7286 pigs from three different pure breeds using the FarmCPU model. The genetic and phenotypic variance explained by the four candidate regions is 8.42% and 1.85%, respectively. Twenty-eight candidate genes were detected, of which APPL2, TGFBI, MACROH2A1, and SEC22B have been reported to affect body growth or development. In addition, 21 H3K4me3-enriched peaks overlapped with the birth weight-associated genomic regions were identified by integrating the genome-wide association study results with our previous ChIP-seq and RNA-seq data generated in the pig placenta, a fetal organ relevant to birth weight, and three of the regulatory regions influence TGFBI, MACROH2A1, and SEC22B expression. This study provides new insights into understanding the mechanisms for birth weight. Further investigating the variants in the regulatory regions would help identify the functional variants for birth weight in pigs.
This study consisted of 5 Visits. Eligible patients underwent allergy testing using the Conjunctival Allergen Challenge (CAC) model, which reproduces the signs and symptoms of Seasonal Allergic Conjunctivitis by replicating the natural disease process. Patients demonstrating a positive reaction to the CAC at Visit 1 (screening) and Visit 2 (confirmatory) were randomized to treatment at Visit 3 (Day 0). The test article was instilled at Visit 3, with treatment efficacy CAC performed at 24 hours duration of action. The test article was instilled again at Visit 4 (Day 14), with treatment efficacy CAC performed at 16 hours duration of action. The test article was instilled a final time at Visit 5 (Day 21), with treatment efficacy performed at onset of action.
PROBLEM TO BE SOLVED: To stabilize collagen fibers in a dispersion formed from a collagen solution or dispersion treated with sodium hydroxide so as to deactivate an infectious substance. SOLUTION: This stabilized dispersion is prepared from a solution, dispersion or suspension of collagen fibers treated with a chemical reagent (e.g. NaOH) so as to deactivate an infectious disease. The dispersion is obtained by a physical fiber stabilizer containing such a kind of a polymer material as to precipitate collagen fibers from a solution at a sufficient concentration. The preferable polymer properties are water-soluble or water-miscible and, for example, a polyethylene glycol may be cited as the polymer. A dispersion is also prepared by using a chemical fiber stabilizer for stabilizing fibers by cross-linking the fibers. A preferable method for stabilizing the collagen fibers is to use a stabilizer after the treatment.
<P>PROBLEM TO BE SOLVED: To provide a protein glycation inhibitor having the ability to inhibit the glycation of a protein such as collagen.  <P>SOLUTION: The protein glycation inhibitor is composed of at least one of an extract of Perilla frutescens (L.) Britton var. acuta Kudo, an extract of Rubus suavissimus Shugan Lee. (Rosaseae), and an extract of Citrus limon Burmann fil (Rutaceae). This protein glycation inhibitor has an excellent ability to inhibit the saccharification of collagen. Accordingly, the protein glycation inhibitor is suitably used as a material of a food and drink product (for example, a supplement and a drink), a drug (for example, a skin external preparation and an oral medicine), a quasi drug or a cosmetic.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The only bilingual Dutch/French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from December 2014.
PURPOSE:To obtain the titled plaster having improved side effect such as dermatic inflammation, etc., by adding a specific steroid agent to a pressure-sensitive adhesive gel substrate containing a water-soluble polymer, water and a water- retaining agent as essential components. CONSTITUTION:The objective external plaster is produced by compounding (A) a pressure-sensitive adhesive gel substrate containing a water-soluble polymer (e.g. gelatin, agar, arginic acid, etc.), water and a water-retaining agent (e.g. polyethylene glycol, glycerol, sorbitol, etc.) as essential components with (B) steroid agent such as fluocinolone acetonide, triamcinolone acetonide, etc. The plaster can be applied continuously without causing the dermatic inflammation, damage of diseased part in peeling and delamination of cuticle, etc., in contrast with a tape agent applied to aczema, urticaria, infantile strophulus, etc. Furthermore, the plaster is expected to have the effect of occlusive dressing technique and gives improved remedying effect by the increase of the absorption of the steroid agent used as a main component.
POMBILITI must be administered in combination with Opfolda (see Figure 1 for the dosing timeline). If the Opfolda dose is missed, POMBILITI should not be administered. Refer to the Opfolda Prescribing Information for Opfolda dosage and administration recommendations.

Prior to POMBILITI administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids [see Warnings and Precautions (5.1, 5.2)]. If premedication was used with previous enzyme replacement therapy (ERT), prior to POMBILITI administration, pretreat with antihistamines, antipyretics, and/or corticosteroids.

The recommended dosage of POMBILITI is 20 mg/kg (of actual body weight) administered every other week as an intravenous infusion over approximately 4 hours (see Table 1 for the recommended total infusion volume based on the patient’s weight).

Start POMBILITI in combination with Opfolda 2 weeks after the last ERT dose.

Initiate the POMBILITI infusion approximately 1 hour after oral administration of Opfolda. If the POMBILITI infusion cannot be started within 3 hours of oral administration of Opfolda, reschedule POMBILITI in combination with Opfolda at least 24 hours after Opfolda was last taken. If POMBILITI in combination with Opfolda are both missed, re-start treatment as soon as possible.

Figure 1. Dosing Timeline